Loma Linda, California 92350

  • Dental Implants


To evaluate the clinical success, stability, radiographic bone level changes and peri-implants soft tissue parameter of the SLActive surface implant supporting single crowns restorations in early loading in the mandibular first molar region.

Study summary:

The human clinical trial will be designed as a longitudinal prospective study. A total of 24 titanium implants with a modified SLA surface (BLT SLActive®, Institute Straumann AG, Basel, Switzerland) will be placed in the mandibular first molar. 12 for the control group and for the 12 test group.


Inclusion Criteria: 1. Patients aged 18 years or older. 2. Willingness to comply with all study requirements. 3. Partially edentulous in the in mandibular first molar with presence of the mandibular second molar 4. Patients of ASA I and ASA II group. No relevant medical conditions such as uncontrolled diabetes mellitus, osteoporosis, malignancies, irradiation and blood dyscrasias. 5. Free from soft tissue mucosal lesions, caries, and active periodontitis at the time of implant insertion. 6. Sufficient alveolar bone volume at the implant recipient site at the time of the insertion. 7. Adequate oral hygiene. Full-mouth plaque score (FMPS) (O'Leary et al. 1972) full-mouth bleeding score (FMBS) (Ainamo & Bay 1975) record as the percentage of surfaces, four per each tooth, patients need to have controlled their periodontal conditions (FMPS 20%, FMBS 20%). Exclusion Criteria: 1. Pregnant or lactating females. 2. Systemic disease likely to compromise implant surgery; uncontrolled diabetes mellitus. 3. History of irradiation in the head and neck area. 4. Smoking. 5. Untreated periodontitis. 6. Alcohol or drug abuse. 7. History of Intravenous Bisphosphonate. 8. Previously augmented or tooth extraction at the intended implant recipient site within the last 6 months. 9. The use of regenerative procedures in conjunction with implant placement. 10. Presence of residual roots at the implant recipient site. 11. Stomatological diseases. 12. Clinical signs of bruxism. 13. Initial stability at least 35Ncm



Primary Contact:

Principal Investigator
Aladdin j Alardah, DDS
associate professor

Bader s albader, DDS
Phone: 9095584983 ext. 0000
Email: balbader@llu.edu

Backup Contact:


Location Contact:

Loma Linda, California 92350
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: September 23, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.